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Key Points
In the presence of a patent foramen ovale (PFO), a tran- sient ischemic attack is indistinguishable from a complex migraine. Both have transient neurologic deficits with a normal MRI.
The size of a PFO by echo should not be a criterion for closure. A stroke or peripheral embolus associated with a PFO is the indication for closure.
Informed consent for PFO closure should include the warning that about 1 in 500 cases require device removal through open-heart surgery.
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Percutaneouspatentforamenovale(PFO)closureisasimpleandsafe
outpatient  procedure that replaces the need for open-heart surgery.
Therearenowfourrandomizedclinicaltrials(RCTs),whichshowthatd
evice  closure  is  preferable  to  standard-of-care  medical
therapytoprevent recurrent stroke in patients with stroke of
unclear  etiology  associated  with  a  PFO.  In  addition  to
stroke,  several  otherconditionsare  associated  with  a  PFO;
the  most  common  are  migraine  withaura  and  transient
neurologic  deficits  without  cephalgia,  such  asvisualmigraine,
recurrent paresthesia, or aphasia. The jury is stilloutwhether
PFO  should  be  closed  to  prevent  migraine,  but  a  new
trialisscheduled to start this year that will address this issue
and  clarify  the  target  patient  population.  PFO  can  also
cause  profound  hypoxemia,  whichisaformofcongenitalright-
to-leftshuntandshouldnotrequire
aRCTtoprovethatclosureistheappropriatemethodoftreatment.
There are several interesting facts about PFO that may
be useful for doctors to discuss with their patients. Since
20% of  all  individuals  have a PFO,  it  is  by far  the most
common congenital heart defect. In
comparison, a bicuspid aortic valve occurs in 1–2% of the
general
population.BecauseaPFOdoesnotcreateamurmur,mostpeoplego
through life without knowing that they have one. However, 50% of
peoplewhohavemigrainewithaurahaveaPFO,soyoucanusethiscli
nical association to consider the diagnosis. The estimated
occur-
renceofstrokeperyearisabout1in1000peoplewithaPFO,solon-
gitudinal  studies  of  populations  are  unlikely  to  identify
anincreasedincidence. Once someone has had a stroke, the
risk of recurrent stroke is 1% per year, and this appears to
be  continuous;  that
is,theriskis10%at10yearsandpresumablytheriskcontinuesatthis
rate. For a young person with a life expectancy of 50 more
years,extrapo- lating from the RCTs suggests that there will be a 50% risk of stroke
recurrence  in  that  person's  lifetime.  The  frequency  of  PFO  in  people
whopresentwithcryptogenicstrokeis60%,andiftheyhavemigraine
with frequent aura, this increases to93%.1
The PFO itself does not cause a stroke but rather serves
as  the  pathwayforaright-to-
leftshunt.Ifavenousclotispresentsecondary  to  conditions  such
as  deep  vein  thrombosis,  varicose  veins,  or  pro-
longedimmobilityfromaplaneorcartrip,thenthethrombusisableto
enter the arterial circulation through the interatrial shunt. This may
explain why migraineurs have a higher risk of stroke. Migraine with
aura is an indication that a PFO pathway may be present, and the
presence of risk factors for thrombus formation, such as exogenous
estrogenuse(birthcontrolorhormonereplacementtherapy),smoking,
orvaricoseveins(anywomanwhohadachild),providestheammuni-
tion to enter the pathway and produces an embolic stroke, renal
infarction, or peripheralembolus.
Although20%ofpeopleingeneralhaveaPFO,thedefectisgeneti-
callydistributed,and60%offirst-
degreerelativesofaprobandwithaPFO-associated  conditionwill
have  a  PFO.  Daughters  of  a  PFO-
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associatedstrokepatientshouldbetestedforthepresenceofaPF
O,
andifoneispresent,Iadvisethemtoavoidusingexogenousestrogen
(birthcontrolpillsorcervicalrings).
Transesophagealechocardiography(TEE)  underestimates
PFO  sizecomparedwith  a  sizing  balloon,  so  that
theanatomicalsize  by  ultra-
soundshouldnotbeacriteriaforclosure.Alargestrokecanoccureven
witha“small”PFO.Thesizeofthethrombusisagreaterdeterminan
t  ofstrokemagnitudethanPFOsize.2ThepresenceofaPFO-
associatedstrokeis  enough  to  justify  closure.  It  is
inconsistent  with  the  data  to
statethatthePFOissmallbyTEEandthereforecouldnotbeculpable.
TheriskofaPFOclosureprocedureshouldbeminimal(<1%).Themaj
or concern is  a 5% risk of new-onset atrial  fibrillation  2–
6weekspost-procedure due to irritation from the device. A
second concern is that 1 in 500 patients develop excessive
scar tissue with chestpain,or more rarely, atrial perforation
with tamponade, which requires surgical removal of the PFO
closure device. Perhaps, a 0.2% risk of open-heart surgery
is  not  terrible  as,  without  these devices,allpatients  would
have undergone surgery or remained at elevatedrisk
1086 TOBIS
for recurrent stroke. However, 0.2% is not a negligible risk,
and  all  patients  should  be  warned  of  this  during  the
informed consent process. The development of new devices
without  these  drawbacks  provides  an  opportunity  for
innovative thinkers.
With  these  observations  as  background,  let  us
interprettheaccompanying  article  by  Snidjer  et  al
(Percutaneous  patent  foramen  ovale  closure  using  the
Occlutech  Figulla  device:  More  than1,300patient-years  of
follow  up).  This  group  from  the  Netherlandspro-vides  an
observational study of 250 people who had the Occlutech
Figulla device placed to close a PFO. The primary reason
(89%) for PFO closure was transient ischemic attack (TIA) or
stroke.  With  a  mean  follow-up  of  5.9  years,  the  risk  of
recurrent stroke was 3% (8/250). The authors arrived at this
value by combining TIA patients and stroke patients but it
should have been calculated using only  the stroke patients.
For  example,  if  they  only  had  150  patientswithMRI-
documented  stroke,  then  the  risk  of  stroke  recurrence
is5%(8/150).  In  the  stroke  RCTs,  the  recurrence  rate  for
medicaltreat-ment  was  1%  per  year,  so  the  Occlutech
device  does  not  impress  one  as  being  superior  to
medicaltherapy. Of course, themajorweakness of this study
is that it is not a RCT, so we do not know how this device
compares with medical therapy or other devices. Speaking
of other devices, those of us in the United States will  never
see  this  device  because  it  was  ruled  to  infringe
ontheAmplatzer PFO Occluder (Abbott, Chicago, IL) patent,
to whichtheOcclutech product is sinisterly similar. But even
using thec u r r e n t
study  data,  the  results  are  not  impressive  because  the
residualshunt rate was fairly high at 6%, and that was derived using
transthoracic  echocardiogram,  an  imaging  modality  less  sensitive
thanotherultrasoundtechniques,suchastranscranialDoppler.Forco
mparison, the Gore Cardioform Septal Occluder (W.L. Gore and
Associates, Flagstaff, AZ) provides effective closure in 99% ofcases.
Lastly, it is clinically impossible to distinguish between
aTIA,whichisthoughttobeembolic,andacomplexmigraine,whichis
pre- sumed to be triggered by a chemical (serotonin or low-
oxygenated venous blood) that bypasses the lungs through the
interatrial shunt. Both entities produce a transient neurological
deficit  with  noabnor-mality  on  brain  magnetic  resonance
imaging.  Authors  of  outcome  studies  that  count  TIA
prevention  as  due  to  the  PFO  closure  maybefooling
themselves  in  that  they  are  actually  inhibiting
migraines,andthe“recurrentstrokerate”wouldnaturallybelow.O
fcourse,botharegoodresults,buttherisksoftheprocedurehaveto
bejustifiedbythe  clinical  syndrome  that  is  purported  to
havebenefitted.
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